Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

RVC and UCL to pioneer research into Parkinson's disease
Researchers will use the funding to explore the possibilities of future prevention and treatment of Parkinson's disease.
Vets to explore the possibilities of future prevention and treatment.

A pioneering study into the causes and progression of Parkinson's disease is to be carried out by the Royal Veterinary College (RVC) in collaboration with University College London (UCL).

The news follows a $7 million grant from Aligning Science Across Parkinson's (ASAP), an initiative that fosters collaboration and resources to better understand the underlying causes of this debilitating disease.

Researchers will use the funding to explore the possibilities of future prevention and treatment of Parkinson's. Specifically, the team will investigate the role of the LRRK2 gene - one of the most common genetic causes of the disease and a priority drug target.

Dr Patrick Lewis, Professor of Neuroscience at the RVC, said: “The Aligning Science Across Parkinson’s foundation grants represents a new way of approaching research into Parkinson’s, with the clear goal of accelerating progress in our understanding of this disorder. It is a real privilege to be involved in this initiative.”

Parkinson's is a progressive brain disorder that causes slowness, stiffness, tremors and walking and balance problems. The condition affects more than 130,000 people in the UK alone, and the only current available treatments help to alleviate symptoms, but not slow progression of the disease.

Professor Jonathan Elliott, vice-principal (Research and Innovation) at the RVC, said: “The RVC is delighted to be part of this large collaborative effort to advance treatments for Parkinson’s Disease. Neurodegenerative conditions significantly impact on the quality of life of our ageing human population in the UK and Professor Lewis’ role in this collaboration is exciting in its potential to uncover new drug targets to slow progressive loss of functioning neurons."

Become a member or log in to add this story to your CPD history

Cold-water dip to raise funds for Vetlife

News Story 1
 The veterinary mental health charity Vetlife is inviting the veterinary community to join it for a sponsored cold-water dip.

The event will take place at Walpole Bay, Margate, on 17 May during Mental Health Awareness Week. Participants of all abilities can join in the challenge and are advised to bring a towel, a hot drink, a snack, and warm clothes to get changed into afterwards.

Those taking part are being asked to try to raise 100 each to support the work of the charity.

Details about how to take part can be found here

Click here for more...
News Shorts
Defra to host bluetongue webinar for vets

The Department for Environment, Food and Rural Affairs (Defra) will be hosting a webinar for veterinary professional on bluetongue on Thursday, 25 April 2024.

Topics covered will include the transmission cycle, pathology and pathogenesis, clinical signs (including signs seen in recent BTV-3 cases in the Netherlands), and control and prevention.

The session, which will take place from 6pm to 7.30pm, is part of Defra's 'Plan, Prevent and Protect' webinar series, which are hosted by policy officials, epidemiologists and veterinary professionals from Defra and the Animal and Plant Health Agency. The bluetongue session will also feature insights from experts from The Pirbright Institute.

Those attending will have the opportunity to ask questions. Places on the webinar can be booked online.